fda warning letters compounded semaglutide november 2025 issued 25 to telehealth companies for false and misleading claims about GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of Beyond the Headlines: FDA Warning
Description
This combination creates conditions where heartburn, regurgitation, or chest discomfort may develop, particularly in the evening or when lying flat
GLP-1 receptor agonists have transformed medical weight loss
Traditional value equals volume messaging is losing relevance, while quality, nutrition, and functional food choices are gaining ground
Semaglutide, manufactured by Novo Nordisk, was approved by the FDA in August for treating MASH, but it is only one type of GLP-1 agonist receptor that could provide treatment options
Did it appear during initiation or after a prescription change
Plus, excessive weight loss of any kind while breastfeeding can impact your milk supply and make it hard to feed your baby
